No Data
Press Release: Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development
Express News | Atossa Therapeutics Appoints Claudia Lopez, Dvm, MSC, as Vice President, Clinical Product Development
Promising Phase 2 Results and Strong Safety Profile Support Buy Recommendation for Atossa Therapeutics
Atossa Therapeutics Reports Phase 2 Data for Breast Cancer Prevention
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:
Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4
No Data
No Data